Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case study reports the first extensively interpreted instance of dystrophic telogen effluvium potentially linked to pegylated interferon and ribavirin therapy for chronic hepatitis C, characterized through clinical and trichogram analysis.

This case report describes a 29-year-old woman with longstanding alopecia areata who experienced improvement in her scalp hair loss after 7 years of topical treatment with squaric acid dibutylester.

This report describes a case of alopecia universalis in a woman with hepatitis C linked to pegylated interferon alfa-2b and ribavirin therapy, with hair regrowth observed one year after discontinuation.

In this report, a case of a bullous lesion developed at the injection site in a patient treated with PEG-IFN-α-2a for chronic hepatitis C was described.

In this study, pegylated interferon alpha therapy was independently associated with more severe hair loss, particularly acute telogen effluvium, in chronic hepatitis B patients with alopecia, compared to nucleos(t)ide analog therapy, emphasizing the importance of monitoring and counseling, especially for younger female patients.